Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients

Phase 4 Terminated 21 enrolled Dong Jie

RandomizedParallel-groupTriple-blindTreatment

Summary

A randomized, double-blind controlled Study from a single center to evaluate the effect and safety of pramipexole on peritoneal dialysis patients with restless legs syndrome

Timeline

Start: 2019-07-01
Primary completion: 2020-08-31
Completion: 2020-08-31

Publications

Ma TT, Yang Z, Zhu S, Zhao JH, Li Y, Sun FY, Zhao N, Xiong ZY, Xiong ZB, Dong J. Pramipexole in peritoneal dialysis patients with restless legs syndrome (RLS): a protocol for a multicentre double-blind randomised controlled trial. BMJ Open. 2020 Feb 18;10(2):e033815. doi: 10.1136/bmjopen-2019-033815.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pramipexole	Unknown	0.125 mg	Oral
Subject	Pramipexole	Unknown	0.25 mg	Oral
Subject	Pramipexole	Unknown	0.5 mg	Oral
Subject	Pramipexole	Unknown	0.75 mg	Oral

Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients

Summary

Timeline

Publications

Drugs

Indications